Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 8/20 | 1.00 |
| ▸ | TACR3 | P29371 | 5/20 | 0.44 |
| ▸ | TACR1 | P25103 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091194 | 1.00 | TACR2 (1.00) | TACR2TACR3TACR1CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL7744616 | 0.98 | TACR2 (0.97) | TACR2TACR3TACR1CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL7744615 | 0.98 | TACR2 (0.97) | TACR2TACR3TACR1CYP3A4CYP2D6 | |
| Succinic Acid SCHEMBL7716780 | 0.97 | TACR2 (0.94) | TACR2TACR3TACR1CYP3A4CYP2D6 | |
| Succinic Acid SCHEMBL7716777 | 0.97 | TACR2 (0.94) | TACR2TACR3TACR1CYP3A4CYP2D6 | |
| Fumaric Acid SCHEMBL7719837 | 0.96 | TACR2 (0.93) | TACR2TACR3TACR1CYP3A4CYP2D6 | |
| Fumaric Acid SCHEMBL7719845 | 0.96 | TACR2 (0.93) | TACR2TACR3TACR1CYP3A4CYP2D6 | |
| Fumaric Acid SCHEMBL7751878 | 0.96 | TACR2 (0.93) | TACR2TACR3TACR1CYP3A4CYP2D6 | |
| Fumaric Acid SCHEMBL7719842 | 0.96 | TACR2 (0.93) | TACR2TACR3TACR1CYP3A4CYP2D6 | |
| SCHEMBL4631279 | 0.92 | TACR2 (0.85) | TACR2TACR3TACR1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090795-A1 | Pharmaceutical Compositions Based on Nk2 Antagonists for Pediatric Use | LABORATORI GUIDOTTI S.P.A. (IT) | 2008-04-17 | — | — | US | claimed |
| EP-1809267-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON NK2 ANTAGONISTS FOR PEDIATRIC USE | Laboratori Guidotti S.P.A. (IT) | 2007-07-25 | — | — | EP | claimed |
| WO-2006045820-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON NK2 ANTAGONISTS FOR PEDIATRIC USE | LABORATORI GUIDOTTI S.P.A. (IT) | 2006-05-04 | — | — | WO | claimed |
| EP-1140923-B1 | METHOD FOR PREPARING (R)- (+) -3 1- 2-( 4-BENZOYL- 2-(3,4- DIFLUOROPHENYL)MORPHOLIN- 2-YL)ETHYL]- 4-PHENYLPIPERIDIN -4-YL -1,1- DIMETHYLUREA, ITS SALTS SOLVATES AND/OR HYDRATES | SANOFI SYNTHELABO (FR) | 2003-03-05 | — | — | EP | claimed |
| US-6392039-B1 | COUPLING; SALT FORMATION | SANOFI-SYNTHELABO (FR) | 2002-05-21 | — | — | US | claimed |
| US-20100234284-A1 | Pharmaceutical compositions based on NK2 antagonists for pediatric use | ALEOTTI ALBERTO | 2010-09-16 | — | — | US | disclosed |
| US-7727955-B2 | Pharmaceutical compositions based on NK2 antagonists for pediatric use | LABORATORI GUIDOTTI S.P.A. (IT) | 2010-06-01 | — | — | US | disclosed |
| US-7378521-B2 | Preparation of 2-(2-arylmorpholin-2-yl) ethanol derivatives and intermediates | SANOFI-AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| US-20080090795-A1 | Pharmaceutical Compositions Based on Nk2 Antagonists for Pediatric Use | LABORATORI GUIDOTTI S.P.A. (IT) | 2008-04-17 | — | — | US | disclosed |
| EP-1809267-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON NK2 ANTAGONISTS FOR PEDIATRIC USE | Laboratori Guidotti S.P.A. (IT) | 2007-07-25 | — | — | EP | disclosed |
| US-20070167623-A1 | PREPARATION OF 2-(2-ARYLMORPHOLIN-2-YL) ETHANOL DERIVATIVES AND INTERMEDIATES | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | disclosed |
| US-7223860-B2 | Preparation of 2-(2-arylmorpholin-2-yl) ethanol derivatives and intermediates | SANOFI-AVENTIS (FR) | 2007-05-29 | — | — | US | disclosed |
| EP-1200417-A1 | METHOD FOR PREPARING 2-(2-ARYLMORPHOLIN-2-YL)ETHANOL DERIVATIVES AND INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 2002-05-02 | — | — | EP | disclosed |
| CN-1334813-A | Method for preparing (R)-(+)-3-{1-[2-(4-benzoyl-2-(3,4-difluorophenyl) morpholin-2-yl)ethyl]-4-phenylpiperdin-4-yl}-1,1-dimethylurea, its salts solvates and/or hydrates | SANOFI SYNTHELABO (FR) | 2002-02-06 | — | — | CN | disclosed |
| CN-1334813-A | Method for preparing (R)-(+)-3-{1-[2-(4-benzoyl-2-(3,4-difluorophenyl) morpholin-2-yl)ethyl]-4-phenylpiperdin-4-yl}-1,1-dimethylurea, its salts solvates and/or hydrates | SANOFI SYNTHELABO (FR) | 2002-02-06 | — | — | CN | disclosed |
| EP-1140923-A1 | METHOD FOR PREPARING (R)- (+) -3 1- 2-( 4-BENZOYL- 2-(3,4- DIFLUOROPHENYL)MORPHOLIN- 2-YL)ETHYL]- 4-PHENYLPIPERIDIN -4-YL -1,1- DIMETHYLUREA, ITS SALTS SOLVATES AND/OR HYDRATES | SANOFI-SYNTHELABO (FR) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001004105-A1 | METHOD FOR PREPARING 2-(2-ARYLMORPHOLIN-2-YL)ETHANOL DERIVATIVES AND INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 2001-01-18 | — | — | WO | disclosed |
| WO-2000039126-A1 | METHOD FOR PREPARING (R)- (+) -3 {1- [2-( 4-BENZOYL- 2-(3,4- DIFLUOROPHENYL)MORPHOLIN- 2-YL)ETHYL]- 4-PHENYLPIPERIDIN -4-YL}-1,1- DIMETHYLUREA, ITS SALTS SOLVATES AND/OR HYDRATES | SANOFI-SYNTHELABO (FR) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000039126-A1 | METHOD FOR PREPARING (R)- (+) -3 {1- [2-( 4-BENZOYL- 2-(3,4- DIFLUOROPHENYL)MORPHOLIN- 2-YL)ETHYL]- 4-PHENYLPIPERIDIN -4-YL}-1,1- DIMETHYLUREA, ITS SALTS SOLVATES AND/OR HYDRATES | SANOFI-SYNTHELABO (FR) | 2000-07-06 | — | — | WO | disclosed |
| US-6057379-A | IMIDATION BY ADDING MIXTURE OF AROMATIC AND ALIPHATIC DIAMINES TO AROMATIC DICARBOXYLIC ESTER OR ITS ANHYDRIDE TO FORM PRECURSOR, FOAMING, CURING; ADIABATIC MATERIAL, ACOUSTIC ABSORBENT, CUSHIONS IN AEROSPACE, SHIPS,TRAINS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167623-A1 | PREPARATION OF 2-(2-ARYLMORPHOLIN-2-YL) ETHANOL DERIVATIVES AND INTERMEDIATES | ADH1C, ADH1A, ADH5 | TACR2 40/4885TACR3 789/4885TACR1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.